These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35471988)

  • 21. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.
    Supangat ; Sakinah EN; Nugraha MY; Qodar TS; Mulyono BW; Tohari AI
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):58. PubMed ID: 34641944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Kaur U; K L A; Chauhan M; Joshi A; Das A; Kansal S; Jaisawal V; Patwardhan K; Chakrabarti SS
    Drug Saf; 2022 Oct; 45(10):1099-1109. PubMed ID: 36030299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria.
    Shragai T; Adegoke OJ; Ikwe H; Sorungbe T; Haruna A; Williams I; Okonkwo R; Onu K; Asekun A; Gberikon M; Iwara E; Abimiku A; Rufai A; Okposen B; Gidudu J; Lam E; Bolu O
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
    Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
    Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. General determination of causation between Covid-19 vaccines and possible adverse events.
    Hampton LM; Aggarwal R; Evans SJW; Law B
    Vaccine; 2021 Mar; 39(10):1478-1480. PubMed ID: 33558107
    [No Abstract]   [Full Text] [Related]  

  • 27. Annual report: surveillance of adverse events following immunisation in Australia, 2008.
    Menzies R; Mahajan D; Gold MS; Roomiani I; McIntyre P; Lawrence G
    Commun Dis Intell Q Rep; 2009 Dec; 33(4):365-81. PubMed ID: 20301966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia.
    Baxter CM; Clothier HJ; Perrett KP
    Hum Vaccin Immunother; 2018; 14(8):2088-2092. PubMed ID: 29624467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 vaccine counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study.
    Zeng M; Zhai X; Chang H; Feng T; Zhu Y; Ma W; Wang X; Ge Y
    Hum Vaccin Immunother; 2022 Nov; 18(5):2082207. PubMed ID: 35759787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
    Lawrence GL; Boyd I; McIntyre PB; Isaacs D
    Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Feb; 79(2):269-278. PubMed ID: 36527455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annual report: surveillance of adverse events following immunisation in Australia, 2007.
    Lawrence G; Gold MS; Hill R; Deeks S; Glasswell A; McIntyre PB
    Commun Dis Intell Q Rep; 2008 Dec; 32(4):371-87. PubMed ID: 19374268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of adverse events following immunisation in Australia annual report, 2020.
    Dey A; Wang H; Quinn H; Pillsbury A; Hickie M; Deng L; Wood N; Beard F; Macartney K
    Commun Dis Intell (2018); 2022 Jul; 46():. PubMed ID: 35860867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of adverse events following immunisation in Australia: annual report, 2018.
    Dey A; Wang H; Quinn H; Pillsbury A; Glover C; Hickie M; Wood N; Beard F; Macartney K
    Commun Dis Intell (2018); 2020 Mar; 44():. PubMed ID: 32178607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of adverse events following immunisation in Australia annual report, 2013.
    Mahajan D; Dey A; Cook J; Harvey B; Menzies R; Macartney K
    Commun Dis Intell Q Rep; 2015 Sep; 39(3):E369-86. PubMed ID: 26620351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.